Belgium· BE-AMP-SAM500906-00
Darzalex 20 mg/ml
A daratumumab product containing daratumumab, registered in Belgium by Janssen-Cilag International. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Daratumumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FC01 (daratumumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Daratumumab · ATC L01FC01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Daratumumab
- Manufacturer
- Janssen-Cilag International
- Country
- Belgium (BE)
- ATC code
- L01FC01
- ATC class
- Daratumumab
- Defined daily dose
- 64.3 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb7718232
- be_apb4648945
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
72 interactions on record for daratumumab.
Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Daratumumab · interactions on record
72 records
- 29 severe
- 43 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Daratumumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesDARZALEXJanssen Biotech, Inc.
- CzechiaDARZALEXJanssen-Cilag International N.V., Beerse
- FinlandDarzalexParanova Oy
- NorwayDarzalexAbacus Medicine A/S
- IrelandDARZALEX 20 mg/mL concentrate for solution for infusionJanssen-Cilag International NV
- PolandDarzalexJanssen-Cilag International N.V.
- SwedenDARZALEX 20 mg/ml Koncentrat till infusionsvätska, lösningJanssen-Cilag International NV
- IcelandDarzalexJanssen-Cilag International NV*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Darzalex
- Liechtenstein · Darzalex
- Norway · Darzalex
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e6761463-34e1-489b-ba15-e32db4003c93 GET /v1/drugs/e6761463-34e1-489b-ba15-e32db4003c93?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Darzalex 20 mg/ml",
"name_fr": "Darzalex 20 mg/ml",
"name_nl": "Darzalex 20 mg/ml",
"amp_code": "SAM500906-00",
"strengths": [
"20.0000",
"1.8600"
],
"pack_count": 2,
"substances": [
"Daratumumab",
"Mannitol",
"Polysorbate 20",
"Sodium"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Daratumumab",
"authorisation_numbers": [
"EU/1/16/1101/002"
]
}See everything about daratumumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.